TargetMol

CCG-63802

Product Code:
 
TAR-T14897
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T14897-5mg5mg£116.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T14897-10mg10mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T14897-25mg25mg£242.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T14897-50mg50mg£388.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
CCG-63802 is a reversible small-molecule inhibitor of regulator of G protein signaling (RGS) proteins. CCG-63802 inhibits the interaction between RGS4 and Galpha with an IC50 value of 1.4 μM.
CAS:
620112-78-9
Formula:
C26H18N4O2S
Molecular Weight:
450.52
Pathway:
GPCR/G Protein
Purity:
0.98
SMILES:
Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2C=C(/C#N)c2nc3ccccc3s2)c1
Target:
GTPase

References

1. Blazer LL, et al. Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins. Mol Pharmacol. 2010 Sep;78(3):524-33. 2. Meng X, et al. PPAR? Agonist PGZ Attenuates OVA-Induced Airway Inflammation and Airway Remodeling via RGS4 Signaling in Mouse Model. Inflammation. 2018 Jul 19. 3. Bosier B, et al. Inhibition of the regulator of G protein signalling RGS4 in the spinal cord decreases neuropathic hyperalgesia and restores cannabinoid CB1 receptor signalling. Br J Pharmacol. 2015 Nov;172(22):5333-46.